Suppr超能文献

在一个全国性的跨性别和性别非二元成年人样本中,过去 12 个月处方药滥用的流行率和少数群体压力相关因素:来自美国跨性别调查的结果。

Prevalence and minority-stress correlates of past 12-month prescription drug misuse in a national sample of transgender and gender nonbinary adults: Results from the U.S. Transgender Survey.

机构信息

Columbia University Irving Medical Center, 622 W. 168(th) Street, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA.

Columbia University Irving Medical Center, 622 W. 168(th) Street, New York, NY 10032, USA.

出版信息

Drug Alcohol Depend. 2021 Feb 1;219:108474. doi: 10.1016/j.drugalcdep.2020.108474. Epub 2020 Dec 21.

Abstract

BACKGROUND

Prescription drug (PD) misuse, particularly opioid misuse, is a major US public health concern. While transgender and gender nonbinary (TGNB) individuals experience numerous health disparities, including substance use disparities, little research has focused on PD misuse in this population.

METHODS

Data for this secondary analysis come from the US Transgender Survey (N = 26,689). First, we examined bivariate differences in past 12-month PD misuse among binary transgender women, binary transgender men, nonbinary individuals assigned-female-at-birth (AFAB), and nonbinary individuals assigned-male-at-birth (AMAB). We then used multivariable logistic regression (separately based on sex-assigned-at-birth) to examine the relationship between gender-identity related discrimination and PD misuse.

RESULTS

PD misuse was significantly more common among binary transgender men (17.3 %), nonbinary AFAB individuals (18.7 %), and nonbinary AMAB individuals (18.0 %); compared to binary transgender women (13.5 %). In multivariable analyses, nonbinary identity was associated with higher odds of PD misuse among TGNB AFAB individuals (OR = 1.121; 95 %CI 1.021-1.232) and AMAB individuals (OR = 1.315; 95 % CI 1.133-1.527). Controlling for overall health status and psychological distress, public accommodations discrimination was associated with PD misuse among TGNB AMAB individuals (OR = 1.578, 95 %CI 1.354-1.839). Among both groups, healthcare discrimination was associated with PD misuse (AFAB OR = 1.388, 95 %CI 1.255-1.534; AMAB OR = 1.227, 95 %CI 1.073-1.404).

CONCLUSION

In this national sample of TGNB individuals, nonbinary individuals were at greater risk for PD misuse than binary individuals, possibly due to less societal affirmation. Similar to other TGNB health disparities, discrimination based on gender identity/expression was associated with PD misuse. This highlights the importance of interventions to reduce discrimination against TGNB individuals.

摘要

背景

处方药物(PD)滥用,尤其是阿片类药物滥用,是美国一个主要的公共卫生关注点。尽管跨性别和性别多样化(TGNB)个体经历了许多健康差异,包括物质使用方面的差异,但很少有研究关注这个群体中的 PD 滥用问题。

方法

本二次分析的数据来自美国跨性别者调查(N=26689)。首先,我们检查了二元跨性别女性、二元跨性别男性、出生时被指定为女性(AFAB)的非二元个体和出生时被指定为男性(AMAB)的非二元个体在过去 12 个月 PD 滥用方面的单变量差异。然后,我们使用多变量逻辑回归(分别基于出生时的性别分配)来检查性别认同相关歧视与 PD 滥用之间的关系。

结果

PD 滥用在二元跨性别男性(17.3%)、非二元 AFAB 个体(18.7%)和非二元 AMAB 个体(18.0%)中明显更为常见;而二元跨性别女性的 PD 滥用率为 13.5%。在多变量分析中,非二元性别认同与 TGNB AFAB 个体(OR=1.121;95%CI 1.021-1.232)和 AMAB 个体(OR=1.315;95%CI 1.133-1.527)的 PD 滥用风险增加相关。在控制整体健康状况和心理困扰后,公共场所歧视与 TGNB AMAB 个体的 PD 滥用相关(OR=1.578,95%CI 1.354-1.839)。在这两个群体中,医疗保健歧视与 PD 滥用相关(AFAB OR=1.388,95%CI 1.255-1.534;AMAB OR=1.227,95%CI 1.073-1.404)。

结论

在这个全国性的 TGNB 个体样本中,非二元个体比二元个体更有可能滥用 PD,这可能是由于他们较少得到社会的认可。与其他 TGNB 健康差异一样,基于性别认同/表达的歧视与 PD 滥用相关。这突显了减少针对 TGNB 个体的歧视的干预措施的重要性。

相似文献

2
Mental Health Status of Cisgender and Gender-Diverse Secondary School Students in China.
JAMA Netw Open. 2020 Oct 1;3(10):e2022796. doi: 10.1001/jamanetworkopen.2020.22796.
3
Correlates of hazardous alcohol drinking among trans and non-binary people in Canada: A community-based cross-sectional study.
Drug Alcohol Depend. 2023 Sep 1;250:110872. doi: 10.1016/j.drugalcdep.2023.110872. Epub 2023 Jun 24.
5
Transgender/nonbinary young adults' exposure to cissexism-related social stressors: Variation across gender groups.
Soc Sci Med. 2023 Jul;329:116013. doi: 10.1016/j.socscimed.2023.116013. Epub 2023 Jun 9.
6
Suicidal Ideation Disparities Among Transgender and Gender Diverse Compared to Cisgender Community Health Patients.
J Gen Intern Med. 2023 May;38(6):1357-1365. doi: 10.1007/s11606-022-07996-2. Epub 2023 Jan 17.
8
Impact of Bathroom Discrimination on Mental Health Among Transgender and Nonbinary Youth.
J Adolesc Health. 2021 Jun;68(6):1142-1147. doi: 10.1016/j.jadohealth.2020.11.001. Epub 2020 Dec 4.
9
Stigmatization, Resilience, and Mental Health Among a Diverse Community Sample of Transgender and Gender Nonbinary Individuals in the U.S.
Arch Sex Behav. 2020 Oct;49(7):2649-2660. doi: 10.1007/s10508-020-01761-4. Epub 2020 Jun 23.

引用本文的文献

1
Substance Use Prevalence Among Transgender and Gender Diverse Young Adults Across Identity and Life Experiences.
Ann LGBTQ Public Popul Health. 2025 Jul;6(2):200-214. doi: 10.1891/lgbtq-2023-0037.
3
Postoperative Opioid Prescription Size and Patient-reported Consumption Following Gender-affirming Mastectomy: A Prospective Survey Study.
Plast Reconstr Surg Glob Open. 2025 Aug 4;13(8):e7023. doi: 10.1097/GOX.0000000000007023. eCollection 2025 Aug.
5
Transgender and Gender-Diverse Minority Stress and Substance Use Frequency and Problems: Systematic Review and Meta-Analysis.
Transgend Health. 2025 Feb 10;10(1):7-21. doi: 10.1089/trgh.2023.0025. eCollection 2025 Feb.
6
Substance use patterns among a global sample of transgender and non-binary people during the COVID-19 pandemic.
BMC Glob Public Health. 2023 Sep 18;1(1):16. doi: 10.1186/s44263-023-00014-5.
7
Enhanced Recovery Protocol Decreases Postoperative Opioid Use after Penile Inversion Vaginoplasty.
Plast Reconstr Surg Glob Open. 2024 Nov 8;12(11):e6279. doi: 10.1097/GOX.0000000000006279. eCollection 2024 Nov.
8
Problems in management of medication overuse headache in transgender and gender non-conforming populations.
Front Neurol. 2024 Jan 30;15:1320791. doi: 10.3389/fneur.2024.1320791. eCollection 2024.
9
Substance Use Over Time Among Sexual and Gender Minority People: Differences at the Intersection of Sex and Gender.
LGBT Health. 2024 May-Jun;11(4):269-281. doi: 10.1089/lgbt.2023.0055. Epub 2024 Jan 11.
10
Psychopharmacological Considerations for Gender-Affirming Hormone Therapy.
Harv Rev Psychiatry. 2023;31(4):183-194. doi: 10.1097/HRP.0000000000000373.

本文引用的文献

1
Non-binary and binary transgender youth: Comparison of mental health, self-harm, suicidality, substance use and victimization experiences.
Int J Transgend. 2017 Sep 18;20(2-3):230-240. doi: 10.1080/15532739.2017.1370627. eCollection 2019.
2
Gender differences in prescription opioid use and misuse: Implications for men's health and the opioid epidemic.
Prev Med. 2020 Feb;131:105946. doi: 10.1016/j.ypmed.2019.105946. Epub 2019 Dec 6.
4
Comparing the health of non-binary and binary transgender adults in a statewide non-probability sample.
PLoS One. 2019 Aug 27;14(8):e0221583. doi: 10.1371/journal.pone.0221583. eCollection 2019.
7
Sexual Orientation Disparities in Prescription Opioid Misuse Among U.S. Adults.
Am J Prev Med. 2019 Jan;56(1):17-26. doi: 10.1016/j.amepre.2018.07.032. Epub 2018 Nov 19.
8
Risk and Protective Factors for Substance Use among Sexual and Gender Minority Youth: A Scoping Review.
Curr Addict Rep. 2018 Jun;5(2):158-173. doi: 10.1007/s40429-018-0196-9. Epub 2018 May 26.
10
Self-Reported Physical and Mental Health of Gender Nonconforming Transgender Adults in the United States.
LGBT Health. 2018 Oct;5(7):443-448. doi: 10.1089/lgbt.2017.0275. Epub 2018 Sep 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验